Skip to main content

Advertisement

SpringerLink
Log in

Comparative Tolerability of Treatments for Juvenile Idiopathic Arthritis

  • Review Article
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Juvenile idiopathic arthritis (JIA) includes several forms of chronic arthritis in children. Treatments are chosen according to the type and severity of the disease. Nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids remain the mainstays of therapy. Traditional slower acting anti-rheumatic drugs, such as gold therapy, penicillamine, sulfasalazine, tiopronin and hydroxychloroquine, are usually poorly active in children. In addition, adverse effects are common, including severe macrophage activation syndrome with gold therapy or sulfasalazine. Low dose, once weekly methotrexate has emerged as the therapeutic agent of choice for children who fail to respond adequately to the administration of an NSAID, especially in those with the extended oligoarticular subtype of the disease. Other immunosuppressive agents, such as cyclosporin, are sometimes combined with methotrexate. In recent years, novel treatments have been developed. Autologous hematopoietic stem cell transplantation is effective in a number of children with severe JIA, whose disease has been refractory to conventional therapy. However, only short term follow-up data are currently available for this novel therapy. In addition, severe infections complicated by macrophage activation syndrome and death have been reported. Finally, anti-tumour necrosis factor-α therapy has shown efficacy in more than two-thirds of children with JIA and polyarthritis, and other cytokine inhibitors may be soon available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI
Table VII

Similar content being viewed by others

References

  1. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol 1998; 25: 1991–4

    PubMed  CAS  Google Scholar 

  2. Brewer EJ, Bass J, Baum J, et al. Current proposed revision JRA criteria. Arthritis Rheum 1977; 20 Suppl. : 195–9

    PubMed  Google Scholar 

  3. European League Against Rheumatism (EULAR). Bulletin 3: the care of rheumatic children. Nomenclature and classification of arthritis in children. Basel: National Zeitung AG. E Munthe, 1977: 47–50

    Google Scholar 

  4. Malleson PN, Petty RE. Remodelling the pyramid: a paediatric perspective. J Rheumatol 1990; 17: 867–8

    PubMed  CAS  Google Scholar 

  5. Wallace CA, Levinson JE. Juvenile rheumatoid arthritis: outcome and treatment for the 1990’s. Rheum Dis Clin North Am 1991; 17: 891–905

    PubMed  CAS  Google Scholar 

  6. Schaller JG. Therapy for childhood rheumatic diseases: have we been doing enough? Arthritis Rheum 1993; 36: 65–70

    Article  PubMed  CAS  Google Scholar 

  7. Lehman TJ. Aggressive therapy for childhood rheumatic diseases: when are immunosuppressives appropriate? Arthritis Rheum 1993; 36: 71–4

    Article  PubMed  CAS  Google Scholar 

  8. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 inhibitor selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 413–21

    Article  PubMed  CAS  Google Scholar 

  9. Golden BD, Abramson SB. Selective cyclo-oxygenase-2 inhibitors. Rheum Dis Clin North Am 1999; 25 (104): 413–21

    Google Scholar 

  10. Walker J, Smith M, Ford-Hutchinson AW. Anti-inflammatory drugs, prostaglandins and leukocyte migration. Agents Actions 1976; 6: 602–6

    Article  PubMed  CAS  Google Scholar 

  11. Forest MJ, Brooks PM. Mechanisms of action of nonsteroidal anti-inflammatory drugs. Bailleres Clin Rheumatol 1988; 2: 275–94

    Article  Google Scholar 

  12. Diamant-Berger MS. Du rhumatisme noueux (polyarthrite déformante) chez les enfants. Paris: Lecrosnier et Babe Libraires, Editeurs Thèse, 1891

    Google Scholar 

  13. Levy G. Clinical pharmacokinetics of aspirin. Pediatrics 1978; 62 Suppl. : 867–72

    PubMed  CAS  Google Scholar 

  14. Kauffman RE, Roberts RJ. Aspirin use and Reye syndrome. Pediatrics 1987; 79: 1049–50

    PubMed  CAS  Google Scholar 

  15. Favara BE, Feller AC, Pauli M, et al. Contemporary classification of histiocytosis disorders. The WHO Committee on Histiocytic/Reticulum Cell Proliferations: Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol 1997; 29: 157–66

    Article  PubMed  CAS  Google Scholar 

  16. Prieur AM, Stephan JL. Macrophage activation syndrome in pediatric rheumatic diseases. Rev Rhum Engl Ed 1994; 6: 385–8

    Google Scholar 

  17. Baron KS, Person DA, Brewer EJ. The toxicity of non steroidal anti-inflammatory drugs in juvenile rheumatoid arthritis. J Rheumatol 1982; 9: 149–55

    Google Scholar 

  18. Mulderg AE, Linz C, Bern E, et al. Identification of non steroidal anti-inflammatory drug-induced gastro-intestinal injury in children with juvenile rheumatoid arthritis. J Pediatr 1993; 122: 647–9

    Article  Google Scholar 

  19. Hermaszewski R, Hayllar J, Woo P. Gastro-intestinal damage due to anti-inflammatory drugs in children. Br J Rheumatol 1993; 32: 69–72

    Article  PubMed  CAS  Google Scholar 

  20. Garazian M, Berkovitch M, Kuren G, et al. Experience with misoprostol therapy for NSAID gastropathy in children. Ann Rheum Dis 1995; 54: 277–80

    Article  Google Scholar 

  21. Levy ML, Barron KS, Echenfield J, et al. Naproxen-induced pseudoporphyria: a distinctive photodermatosis. J Pediatr 1990; 117: 660–4

    Article  PubMed  CAS  Google Scholar 

  22. Wallace CA, Farrow D, Sherry DD. Increased risk of facial scars in children taking non steroidal anti-inflammatory drugs. J Pediatrics 1994; 125: 819–22

    Article  CAS  Google Scholar 

  23. Brooks PM. Side effects of non steroidal anti-inflammatory drugs. Med J Aust 1988; 146: 248–51

    Google Scholar 

  24. Fries JF, Williams CA, Bloch DA. The relative toxicity of non-steroidal anti-inflammatory drugs. Arthritis Rheum 1991; 34: 1353–60

    Article  PubMed  CAS  Google Scholar 

  25. Grondin C, Malleson P, Petty RE. Slow-acting antirheumatic drugs in chronic arthritis. Semin Arthritis Rheum 1988; 18: 38–47

    Article  PubMed  CAS  Google Scholar 

  26. Giannini EH, Cassidy JT, Brewer EJ, et al. Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. Semin Arthritis Rheum 1993; 23: 34–6

    Article  PubMed  CAS  Google Scholar 

  27. Sairanen E, Laaksonen AL. The results of gold therapy in juvenile rheumatoid arthritis. Ann Paediatr Fenn 1963; 8: 105–10

    Google Scholar 

  28. Myers AR. Chrysotherapy in rheumatoid arthritis. Mod Treat 1971; 8: 761–8

    PubMed  CAS  Google Scholar 

  29. Brewer EJ, Giannini EH, Barkley E. Gold therapy with management of juvenile rheumatoid arthritis. Arthritis Rheum 1980; 23: 404–11

    Article  PubMed  Google Scholar 

  30. Davis P. Undesirable side effects of gold salts. J Rheumatol 1979; 6: 18–24

    Google Scholar 

  31. Silverman ED, Miller FJ III, Bernstein B, et al. Consumption coagulopathy associated with systemic juvenile rheumatoid arthritis. J Pediatr 1983; 103: 872–6

    Article  PubMed  CAS  Google Scholar 

  32. Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr 1985; 106: 561–6

    Article  PubMed  CAS  Google Scholar 

  33. Jacobs JC. The hazards of gold injections in children with juvenile rheumatoid arthritis: comment on the article by Lehman. Arthritis Rheum 1993; 36: 1636

    Article  PubMed  CAS  Google Scholar 

  34. Husserl FE, Shuler SE. Gold nephropathy in juvenile rheumatoid arthritis. Am J Dis Child 1979; 133: 51–2

    Google Scholar 

  35. Pegg SJ, Lang BA, Mikhail EL, et al. Fatal bronchiolitis obliterans in a patient with rheumatoid arthritis receiving chrysotherapy. J Rheumatol 1994; 21: 549–51

    PubMed  CAS  Google Scholar 

  36. Giannini EH, Brewer EJ, Person DA. Auranofin in the treatment of juvenile rheumatoid arthritis. J Pediatr 1983; 102: 138–41

    Article  PubMed  CAS  Google Scholar 

  37. Kvien TK, Hoyeraal HM, Sanstad B, et al. Oral gold (auranofin) in juvenile rheumatoid arthritis: a 48-week phase II study. Clin Rheumatol 1984; 3: 551–2

    Article  PubMed  CAS  Google Scholar 

  38. Giannini EH, Brewer EJ, Person DA, et al. Long-term auranofin therapy in patients with juvenile rheumatoid arthritis. J Rheumatol 1986; 13: 768–70

    PubMed  CAS  Google Scholar 

  39. Giannini EH, Brewer EJ, Kuzmina N, et al. Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. Arthritis Rheum 1990; 33: 466–76

    Article  PubMed  CAS  Google Scholar 

  40. Deutsch HF, Morton JI. Dissociation of human serum macro-globulins. Science 1957; 125: 600–1

    Article  PubMed  CAS  Google Scholar 

  41. Schairer H, Stoeber E. Long term follow-up of 235 cases of juvenile rheumatoid arthritis treated with D-penicillamine. In: Munth E, editor. D-penicillamine research in rheumatoid disease. Oslo: Fabritius & Sonner, 1976: 279–81

    Google Scholar 

  42. Ansell BM, Hall MA. Penicillamine in chronic arthritis of childhood. J Rheumatol 1981; 8 Suppl. 7: 112–5

    Google Scholar 

  43. Kvien TK, Hoyeraal HM, Sanstad B. Slow-acting antirheumatic drugs in patients with juvenile rheumatoid arthritis evaluated in a randomized parallel 50-week clinical trial. J Rheumatol 1985; 12: 533–9

    PubMed  CAS  Google Scholar 

  44. Prieur AM, Piussan C, Manigne P, et al. Evaluation of D-penicillamine in juvenile chronic arthritis. Arthritis Rheum 1985; 28: 376–82

    Article  PubMed  CAS  Google Scholar 

  45. Brewer EJ, Giannini EH, Kuzmina N, et al. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the USA-USSR double-blind placebo-controlled trial. N Engl J Med 1986; 314: 1269–76

    Article  PubMed  CAS  Google Scholar 

  46. Murphy KC, Atkins CJ, Offer RC, et al. Obliterative bronchiolitis in two rheumatoid arthritis patients treated with penicillamine. Arthritis Rheum 1981; 24: 557–60

    Article  PubMed  CAS  Google Scholar 

  47. Swartz MO, Silver RM. D-penicillamine induced polymyositis in juvenile chronic arthritis: report of a case. J Rheumatol 1984; 11: 251–2

    PubMed  CAS  Google Scholar 

  48. Hoult JRS. Pharmacological and biochemical actions of sulphasalazine. Drugs 1986; 32 Suppl. 1: 1–80

    Google Scholar 

  49. Laassila K, Leirisalo-Repo M. Side effects of sulphasalazine in patients with rheumatic diseases or inflammatory bowel diseases. Scand J Rheumatol 1994; 23: 338–40

    Article  Google Scholar 

  50. Besnard M, Debray D, Durand P, et al. Hépatite fulminante chez deux enfants traités par salazopyrine pour une maladie de Crohn. Arch Pediatr 1999; 6: 643–6

    Article  PubMed  CAS  Google Scholar 

  51. Caspi D, Fuchs D, Yaron M. Sulphasalazine induced hepatitis in juvenile rheumatoid arthritis. Ann Rheum Dis 1992; 51: 275–6

    Article  PubMed  CAS  Google Scholar 

  52. Senturk T, Aydintug AO, Duzgun N, et al. Seizures and hepatotoxicity following sulphasalazine administration. Rheumatol Int 1997; 17: 75–7

    Article  PubMed  CAS  Google Scholar 

  53. Kuipers EJ, Vellenga E, De Wolf JTM, et al. Sulfasalazine induced agranulocytosis treated with granulocyte-macrophage colony stimulating factor. J Rheumatol 1992; 19: 621–2

    PubMed  CAS  Google Scholar 

  54. Hertzberger-Ten Cate R, Cats A. Toxicity of sulfasalazine in systemic juvenile chronic arthritis. Clin Exp Rheumatol 1991; 9: 85–8

    Google Scholar 

  55. McCarthy C, Coughlan R. Sulphasalazine desensitisation in patients with arthritis. Ir J Med Sci 1994; 163: 238–9

    Article  PubMed  CAS  Google Scholar 

  56. Kummerle-Deshner J, Danneker G. Sulphasalazine desensitization in apaediatric patient with juvenile chronic arthritis. Acta Paediatr 1995; 84: 952–4

    Article  Google Scholar 

  57. Ozdogan H, Turunc M, Deringol B, et al. Sulphasalazine in the treatment of juvenile rheumatoid arthritis: a preliminary open trial. J Rheumatol 1986; 13: 124–5

    PubMed  CAS  Google Scholar 

  58. Hoza J, Havelka S, Kadlecova T, et al. Sulphasalazine in the treatment of juvenile chronic arthritis. R 1990 20: 71–4

    Google Scholar 

  59. Amsell BM, Hall MA, Loftus JK, et al. A multicentre pilot study of sulphasalazine in juvenile chronic arthritis. Clin Exp Rheumatol 1991; 9: 201–3

    Google Scholar 

  60. Joos R, Veys EM, Mielants H, et al. Sulfasalazine treatment in juvenile chronic arthritis: an open study. J Rheumatol 1991; 18: 880–4

    PubMed  CAS  Google Scholar 

  61. Gedalia A, Barash J, Press J, et al. Sulphasalazine in the treatment of pauci-articular onset juvenile chronic arthritis. Clin Exp Rheumatol 1993; 12: 511–4

    Article  CAS  Google Scholar 

  62. Imundo LF, Jacobs JC. Sulfasalazine therapy for juvenile rheumatoid arthritis. J Rheumatol 1996; 23: 360–6

    PubMed  CAS  Google Scholar 

  63. Van Rossum MA, Fiselier TJ, Franssen MJ, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study. Arthritis Rheum 1998; 41: 808–16

    Article  PubMed  Google Scholar 

  64. King JS. Treatment of cystinuria with a mercaptoproprionylglycine: a preliminary report with some notes on column chromatography of mercaptans. Proc Soc Exp Biol Med 1968; 129: 927–32

    PubMed  CAS  Google Scholar 

  65. Amor B, Mery C, De Gery A. Tiopronin (N-[2-mercaptopropionyl]glycine) in rheumatoid arthritis. Arthritis Rheum 1982; 25: 698–703

    Article  PubMed  CAS  Google Scholar 

  66. Sany J, Combe B, Verdie-Petibon D, et al. Long term tolerability of tiopronin (Acadione) in the treatment of rheumatoid arthritis, a propos of 140 personal cases. Rev Rhum Mal Osteoartic 1990; 57: 105–11

    PubMed  CAS  Google Scholar 

  67. Yasuda M, Nonaka S, Wada T, et al. Additive two DMARD therapy of the patients with rheumatoid arthritis. Clin Rheumatol 1994; 13: 446–54

    Article  PubMed  CAS  Google Scholar 

  68. Houpt JB. A rheumatologist’s verdict on the safety of chloroquine versus hydroxychloroquine: liability in off-label prescribing. J Rheumatol 1999; 26: 1864–6

    PubMed  CAS  Google Scholar 

  69. Laaksonen AL, Koskiahde V, Juva K. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus: a clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine. Scand J Rheumatol 1974; 3: 103–8

    Article  PubMed  CAS  Google Scholar 

  70. Levy GD, Munz SJ, Paschal J, et al. Incidence of hydroxychloroquine retinopathy in 1 207 patients in a large multi-center outpatient practice. Arthritis Rheum 1997; 40: 1482–6

    Article  PubMed  CAS  Google Scholar 

  71. Mavrikakis M, Papazoglou S, Sfikakis PP, et al. Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis 1996; 55: 187–9

    Article  PubMed  CAS  Google Scholar 

  72. Spalton DJ. Retinopathy and antimalarial drugs: the British experience. Lupus 1996; 5 Suppl. 1: S70–2

    Article  PubMed  CAS  Google Scholar 

  73. Pincus P. The paradox of effective therapies but poor long-term outcomes in rheumatoid arthritis. Semin Arthritis Rheum 1992; 21: 2–15

    Article  PubMed  CAS  Google Scholar 

  74. Manners PJ, Ansell BM. Slow-acting antirheumatic drug use in systemic onset juvenile chronic arthritis. Pediatrics 1986; 77: 99–103

    PubMed  CAS  Google Scholar 

  75. Rooney M. Is there a disease-modifying drug for juvenile chronic arthritis? Br J Rheumatol 1992; 31: 635–41

    Article  PubMed  CAS  Google Scholar 

  76. Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity: II. Effect of aminopterin in rheumatoid arthritis and in psoriasis. Am J Med Sci 1951; 22: 176–82

    Article  Google Scholar 

  77. Jolivet J, Cowan KH, Chabner BA, et al. The pharmacology and clinical use of methotrexate. N Engl J Med 1983; 309: 1094–102

    Article  PubMed  CAS  Google Scholar 

  78. Barrera P, Boerbooms AMT, Demacker PNM, et al. Circulating concentrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: effects of a single dose methotrexate. Br J Rheumatol 1994; 33: 1017–24

    Article  PubMed  CAS  Google Scholar 

  79. Russell AG, Miller C. The activity of natural killer cells in patients with rheumatoid arthritis. I: the effect of drugs used in vivo. Clin Exp Rheumatol 1986; 2: 227–9

    Google Scholar 

  80. Olsen N, Murray LM. Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum 1989; 32: 378–85

    Article  PubMed  CAS  Google Scholar 

  81. Thomas R, Carroll GJ. Reduction of leukocyte and interleukin- 1 β concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1993; 36: 1244–52

    Article  PubMed  CAS  Google Scholar 

  82. Segal R, Caspi D, Tishler M, et al. Short term effects of low dose methotrexate on the acute phase reaction in patients with rheumatoid arthritis. J Rheumatol 1989; 16: 914–7

    PubMed  CAS  Google Scholar 

  83. Giannini EH, Cassidy JT, Brewer EJ, et al. Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. Semin Arthritis Rheum 1993; 23: 34–46

    Article  PubMed  CAS  Google Scholar 

  84. Giannini EH, Brewer EJ, Kusmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis: results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N Engl JMed 1992; 326: 1043–9

    Article  CAS  Google Scholar 

  85. Wallace CA, Sherry DD. Preliminary report of higher dose of methotrexate treatment in juvenile rheumatoid arthritis. J Rheumatol 1992; 19: 1604–7

    PubMed  CAS  Google Scholar 

  86. Reiff A, Shaham B, Wood BP, et al. High doses methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin Exp Rheumatol 1995; 13: 113–8

    PubMed  CAS  Google Scholar 

  87. Albertioni F, Flato B, Seideman, et al. Methotrexate in juvenile rheumatoid arthritis. Evidence of age dependent pharmacokinetics. Eur J Clin Pharmacol 1995; 47: 507–11

    Article  PubMed  CAS  Google Scholar 

  88. Dupuis LL, Koren G, Silverman ED, et al. Influence of food on the bioavailability of oral methotrexate in children. J Rheumatol 1995; 22: 1570–3

    PubMed  CAS  Google Scholar 

  89. Dupuis LL, Koren G, Shore A, et al. Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. J Rheumatol 1990; 17: 1469–73

    PubMed  CAS  Google Scholar 

  90. Wallace CA, Smith AL, Sherry DD. Pilot investigation of naproxen/methotrexate interaction in patients with juvenile rheumatoid arthritis. J Rheumatol 1993; 20: 1764–8

    PubMed  CAS  Google Scholar 

  91. Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993; 20: 1845–9

    PubMed  CAS  Google Scholar 

  92. Teresi ME, Crom WR, Choi KE, et al. Methotrexate bioavailability after oral and intramuscular administration in children. J Pediatr 1987; 110: 788–92

    Article  PubMed  CAS  Google Scholar 

  93. Ravelli A, Gerloni V, Corona F, et al. Oral versus intramuscular methotrexate therapy in juvenile chronic arthritis. Italian Pediatric Rheumatology Study Group. Clin Exp Rheumatol 1998; 16: 181–3

    PubMed  CAS  Google Scholar 

  94. Wallace CA, Bleyer WA, Sherry DD, et al. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum 1989; 32: 677–81

    Article  PubMed  CAS  Google Scholar 

  95. Ravelli A, Di Fuccia G, Molinaro M, et al. Plasma levels after oral methotrexate in children with juvenile arthritis. J Rheumatol 1993; 20: 1573–7

    PubMed  CAS  Google Scholar 

  96. Speckmaier M, Finseiden J, Woo P, et al. Low dose methotrexate in systemic onset juvenile chronic arthritis. Clin Exp Rheumatol 1989; 7: 647–50

    PubMed  CAS  Google Scholar 

  97. Halle F, Prieur AM. Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. Clin Exp Rheumatol 1991; 9: 297–302

    PubMed  CAS  Google Scholar 

  98. Woo P, Wilkes H, Southwood TR, et al. Low dose methotrexate is effective in extended oligoarticular arthritis but not in systemic arthritis of children [abstract]. Arthritis Rheum 1997; 40: S47

    Article  Google Scholar 

  99. Ravelli A, Viola S, Migliavacca D, et al The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. J Pediatr 1999; 135: 316–20

    Article  PubMed  CAS  Google Scholar 

  100. Harel L, Wagner-Weiner L, Poznanski A, et al. Effects of methotrexate on radiologic progression in juvenile rheumatoid arthritis. Arthritis Rheum 1993; 36: 1370–4

    Article  PubMed  CAS  Google Scholar 

  101. Ravelli A, Viola S, Ramenghi B, et al. Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. J Pediatr 1998; 133: 179–80

    Article  Google Scholar 

  102. Weiss AH, Wallace CA, Sherry DD. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis J Pediatr 1998; 133: 266–8

    Article  PubMed  CAS  Google Scholar 

  103. Wallace CA, Sherry DD, Mellins AD, et al. Predicting remission in juvenile rheumatoid arthritis with methotrexate treatment. J Rheumatol 1993; 20: 118–22

    PubMed  CAS  Google Scholar 

  104. Ravelli A, Viola S, Ramenghi B, et al. Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis. J Rheumatol 1995; 22: 1574–6

    PubMed  CAS  Google Scholar 

  105. Cimaz R, Corona F, Scarazatti M, et al. Methotrexate treatment every other week in patients with juvenile chronic arthritis. Br J Rheumatol 1996; 35: 1030–1

    Article  PubMed  CAS  Google Scholar 

  106. Gottlieb BS, Keenan GF, Lu T, et al. Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. Pediatrics 1997; 100: 994–7

    Article  PubMed  CAS  Google Scholar 

  107. Giannini EH, Cassidy JT. Methotrexate in juvenile rheumatoid arthritis: do the benefits outweigh the risks? Drug Saf 1993; 9: 325–39

    Article  PubMed  CAS  Google Scholar 

  108. Truckenbrodt H, Hafner R. Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study. Arthritis Rheum 1986; 29: 801–7

    Article  PubMed  CAS  Google Scholar 

  109. Rose CD, Singsen BH, Eichenfield AH, et al. Safety and efficacy of methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr 1990; 117: 653–9

    Article  PubMed  CAS  Google Scholar 

  110. Graham LD, Myones BL, Rivas-Chacon RF, et al. Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. J Pediatr 1992; 120: 468–73

    Article  PubMed  CAS  Google Scholar 

  111. Walker AM, Funch D, Dreyer NA, et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 1993; 36: 329–35

    Article  PubMed  CAS  Google Scholar 

  112. Kremer JM, Kaye GI, Kaye NW, et al. Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Followup over long treatment intervals and correlation with clinical and laboratory variables. Arthritis Rheum 1995; 38: 1194–203

    Article  PubMed  CAS  Google Scholar 

  113. Kremer JM, Furst DE, Weinblatt ME, et al. Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J Rheumatol 1996; 23: 459–61

    PubMed  CAS  Google Scholar 

  114. Ruderman EM, Crawford JM, Maier A, et al. Histologic liver abnormalities in autopsy series of patients with rheumatoid arthritis. Br J Rheumatol 1997; 36: 210–3

    Article  PubMed  CAS  Google Scholar 

  115. Kremer JM, Alarcon GS, Lightfoot RW, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 316–28

    Article  PubMed  CAS  Google Scholar 

  116. Danao T, Stienbrunner J, Medendorp SV, et al. Methotrexate in juvenile rheumatoid arthritis [abstract]. Arthritis Rheum 1989; 32: S28

    Google Scholar 

  117. Keim D, Ragsdale C, Heidelberger K, et al. Hepatic fibrosis with the use of methotrexate in juvenile rheumatoid arthritis. J Rheumatol 1990; 17: 846–8

    PubMed  CAS  Google Scholar 

  118. Häfner R, Franke J, Löhrs U. Liver biopsies in juvenile chronic arthritis (JCA) with special reference to methotrexate therapy [abstract]. Clin Exp Rheumatol 1994; 12: S124

    Google Scholar 

  119. Kugathasan S, Newman AJ, Dahms BB, et al. Liver biopsy findings in patients with juvenile rheumatoid arthritis receiving long-term, weekly methotrexate therapy. J Pediatr 1996; 128: 149–51

    Article  PubMed  CAS  Google Scholar 

  120. Hashkes PJ, Balistreri WF, Bove KE, et al. The relationship of hepatotoxic risk factors and liver histology in methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr 1999; 134: 47–52

    Article  PubMed  CAS  Google Scholar 

  121. Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum 1992; 35: 138–45

    Article  PubMed  CAS  Google Scholar 

  122. Anaya JM, Diethelm L, Ortiz LA, et al. Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum 1995; 24: 242–54

    Article  PubMed  CAS  Google Scholar 

  123. Searles G, McKendry RJR. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and review of the literature. J Rheumatol 1987; 14: 1164–71

    PubMed  CAS  Google Scholar 

  124. Hilliquin P, Renoux M, Perrot S, et al. Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 1996; 35: 441–5

    Article  PubMed  CAS  Google Scholar 

  125. Smith GJW. The histopathology of pulmonary reactions to drugs. Clin Chest Med 1990; 11: 95–117

    PubMed  CAS  Google Scholar 

  126. Newman ED, Harrington TM. Fatal methotrexate pneumonitis in rheumatoid arthritis. Arthritis Rheum 1988; 12: 1585–6

    Article  Google Scholar 

  127. Van Der Veen MJ, Dekker JJ, Dinant HJ, et al. Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. J Rheumatol 1995; 22: 1766–8

    PubMed  Google Scholar 

  128. Pelucchi A, Lomater C, Gerloni V, et al. Lung function and diffusing capacity for carbon monoxide in patients withjuvenile chronic arthritis: effect of disease activity and low dose methotrexate. Clin Exp Rheumatol 1994; 12: 675–9

    PubMed  CAS  Google Scholar 

  129. Camiciottoli G, Trapani S, Castellani W, et al. Effect on lung function of methotrexate and non-steroidal anti-inflammatory drugs in children with juvenile rheumatoid arthritis. Rheumatol Int 1998; 18: 11–6

    Article  PubMed  CAS  Google Scholar 

  130. Cron R, Sherry DD, Wallace CA. Methotrexate-induced hypersensitivity pneumonitis in a child with juvenile rheumatoid arthritis. J Pediatr 1998; 132: 901–2

    Article  PubMed  CAS  Google Scholar 

  131. Seideman P, Müller-Suur R. Renal effect of aspirin and low dose methotrexate in rheumatoid arthritis. J Rheumatol 1993; 20: 1126–8

    PubMed  CAS  Google Scholar 

  132. Muzaffer MA, Schneider R, Cameron BJ, et al. Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr 1996; 128: 698–700

    Article  PubMed  CAS  Google Scholar 

  133. Falcini F, Taccetti G, Ermini M, et al. Methotrexate-associated appearance and rapid progression of rheumatoid nodules in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 1997; 40: 175–8

    Article  PubMed  CAS  Google Scholar 

  134. Al-Awadhi A, Dale P, McKendry RJR. Pancytopenia associated with low dose methotrexate therapy: a regional survey. J Rheumatol 1993; 20: 1121–5

    PubMed  CAS  Google Scholar 

  135. Carpenter MT, West SG, Vogelgesant SA, et al. Postoperative joint infections in rheumatoid patients on methotrexate therapy. Orthopedics 1991; 19: 207–10

    Google Scholar 

  136. Bridges Jr SL, Lopez-Mendez A, Han KH, et al. Should methotrexate be discontinued before elective orthopedic surgery in patients with rheumatoid arthritis? J Rheumatol 1991; 18: 984–8

    PubMed  Google Scholar 

  137. Perhala RS, Wilke WS, Clough JD, et al. Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. Arthritis Rheum 1991; 34: 146–52

    Article  PubMed  CAS  Google Scholar 

  138. Sany J, Anaya JM, Canovas F, et al. Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. J Rheumatol 1993; 20: 1129–32

    PubMed  CAS  Google Scholar 

  139. Journeau P, Mabesoone F, Touzet Ph, et al. Total hip prosthesis for chronic juvenile arthritis. A review of a series of 34 prostheses. Rev Chir Irthop Reparatrice Appar Mot 1996; 82: 508–21

    CAS  Google Scholar 

  140. Wheeler DL, Vander Griend RA, Wronski TJ, et al. The short- and long-term effects of methotrexate on the rat skeleton. Bone 1995; 16: 215–21

    Article  PubMed  CAS  Google Scholar 

  141. Preston SJ, Diamond T, Scott A, et al. Methotrexate osteopathy in rheumatic disease. Ann Rheum Dis 1993; 52: 582–5

    Article  PubMed  CAS  Google Scholar 

  142. Bianchi ML, Cimaz R, Galbiati E, et al. Bone mass change during methotrexate treatment in patients with juvenile rheumatoid arthritis. Osteoporos Int 1999; 10: 20–5

    Article  PubMed  CAS  Google Scholar 

  143. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed 1998; 65: 267–73

    PubMed  CAS  Google Scholar 

  144. Beauparlant P, Papp K, Haraoui B. The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1999; 29: 146–58

    Article  Google Scholar 

  145. Georgescu L, Paget SA. Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate? Drug Saf1999; 20: 475–87

    Article  PubMed  CAS  Google Scholar 

  146. Padeh S, Sharon N, Schiby G, et al. Hodgkin’s lymphoma in systemic onset juvenile rheumatoid arthritis after treatment with low dose methotrexate. J Rheumatol 1997; 24: 2035–7

    PubMed  CAS  Google Scholar 

  147. Krugman J, Sailer-Hock M, Muller T, et al. Epstein-Barr virus-associated Hodgkin’s lymphoma and Legionella pneumophila infection complicating treatment of juvenile rheumatoid arthritis with methotrexate and cyclosporin A. Hum Pathol 2000; 31: 253–5

    Article  Google Scholar 

  148. Blackburn WD, Alarcon GS. Impotence in three rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1989; 32: 1341–2

    Article  PubMed  Google Scholar 

  149. Segal AM, Kozlowski RD, Steinbrunner JV, et al. Outcome of first trimester exposure to low-dose methotrexate (MTX) in eight pregnant rheumatoid arthritis (RA) patients [abstract]. Arthritis Rheum 1987; 30: S59

    Google Scholar 

  150. Buckley LM, Bullaboy CA, Leichman L, et al. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 1997; 40: 971–3

    Article  PubMed  CAS  Google Scholar 

  151. Ortiz Z, Shea B, Suarez-Almazor ME, et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A meta-analysis of randomized controlled trials. J Rheumatol 1998; 25: 36–43

    PubMed  CAS  Google Scholar 

  152. Suzuki Y, Uehara R, Tajima C, et al. Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate. Risk factors and response to folic acid. Scand J Rheumatol 1999; 28: 273–81

    Article  PubMed  CAS  Google Scholar 

  153. Modesto C, Castro L. Folinic acid supplementation in patients with juvenile rheumatoid arthritis treated with methotrexate. J Rheumatol 1996; 23: 403–4

    PubMed  CAS  Google Scholar 

  154. Alarcon GS, Morgan SL. Folinic acid to prevent side effects of methotrexate in juvenile rheumatoid arthritis. J Rheumatol 1996; 23: 2184–5

    PubMed  CAS  Google Scholar 

  155. Hunt PG, Rose CD, McIlvain Simpson G, et al. The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. J Rheumatol 1997; 24: 2230–2

    PubMed  CAS  Google Scholar 

  156. Ravelli A, Migliavacca D, Viola S, et al. Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin Exp Rheumatol 1999; 17: 625–7

    PubMed  CAS  Google Scholar 

  157. Prieur AM, Balafrej M, Priscelli C, et al. Traitement par le immunosuppresseurs des rhumatismes inflammatoires chroniques de l’enfant. Arch Fr Pediatr 1977; 34: 783–7

    PubMed  CAS  Google Scholar 

  158. Prieur AM, Balafrej M, Griscelli C, et al. Resultats et risques à long terme des traitements immunosuppresseurs dans l’arthrite chronique juvénile à propos de 40 observations. Rev Rhum 1979; 46: 85–90

    PubMed  CAS  Google Scholar 

  159. Palmer RG, Dore CJ, Denman AM. Chlorambucil induced chromosome damage to human lymphocytes is dose dependent and cumulative. Lancet 1984; I: 246–9

    Article  Google Scholar 

  160. Palmer RG, Ansell BM. Acute leukemia related to chlorambucil therapy in juvenile chronic arthritis. Clin Exp Rheumatol 1984; 2: 81–5

    PubMed  CAS  Google Scholar 

  161. Kauppi MJ, Savoilanen HA, Anttila VJ, et al. Increased risk of leukemia in patients with JCA treated with chlorambucil. Acta Pediatr 1996; 85: 248–50

    Article  CAS  Google Scholar 

  162. Guesry P, Lenoir G, Broyer M. Gonadal effects of chlorambucil given to prepubertal and pubertal boys for nephrotic syndrome. J Pediatr 1978; 92: 299–303

    Article  PubMed  CAS  Google Scholar 

  163. Deschenes G, Prieur AM, Hayem F, et al. Renal amyloidosis in juvenile chronic arthritis: evolution after chlorambucil treatment. Pediatr Nephrol 1990; 4: 463–9

    Article  PubMed  CAS  Google Scholar 

  164. Woo P. Complications of juvenile arthritis. An overview including amyloidosis. In: Woo P, White PH, Ansell BM, editors. Paediatric rheumatology update. Oxford: Oxford University Press, 1990: 38–46

    Google Scholar 

  165. Savolainen HA. Chlorambucil in severe juvenile chronic arthritis: longterm followup with special reference to amyloidosis. J Rheumatol 1999; 26: 898–903

    PubMed  CAS  Google Scholar 

  166. Ansell BM. Chlorambucil therapy in juvenile chronic arthritis (juvenile idiopathic arthritis). J Rheumatol 1999; 26: 765–6

    PubMed  CAS  Google Scholar 

  167. Davis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis: a 20-year follow up study. Arthritis Rheum 1995; 38: 1120–7

    Article  Google Scholar 

  168. Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000; 136: 243–7

    Article  PubMed  CAS  Google Scholar 

  169. Shaikov AV, Maximov AA, Speransky AI, et al. Repetitive use of pulse therapy with methylprednisolone and cyclophosphamide in addition to oral methotrexate in children with systemic juvenile rheumatoid arthritis: preliminary results of a long term study. J Rheumatol 1992; 19: 612–6

    PubMed  CAS  Google Scholar 

  170. Wallace CA, Sherry DD. Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 1997; 40: 1852–5

    Article  PubMed  CAS  Google Scholar 

  171. Gonzalez-Crespo MR, Gomez-Reino JJ, Merino R, et al. Menstrual disorders in girls with systemic lupus erythematosus treated with cyclophosphamide. Br J Rheumatol 1995; 34: 737–41

    Article  PubMed  CAS  Google Scholar 

  172. Bogdanovic R, Banicevic M, Cvoric A. Testicular function following cyclophosphamide treatment for childhood nephrotic syndrome: long term follow up study. Pediatr Nephrol 1990; 4: 451–4

    Article  PubMed  CAS  Google Scholar 

  173. Dale I. The treatment of juvenile rheumatoid arthritis with azathioprine. Scand J Rheumatol 1972; 1: 125–7

    Article  PubMed  CAS  Google Scholar 

  174. Kvien TR, Hoyeraal HM, Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind study. J Rheumatol 1986; 13: 118–23

    PubMed  CAS  Google Scholar 

  175. Savoilainen HA, Kautianen H, Isomaki H, et al. Azathioprine in patients with juvenile chronic arthritis: a long term follow up study. J Rheumatol 1997; 24: 2444–50

    Google Scholar 

  176. Fathman GG, Myers BD. Cyclosporine therapy for autoimmune disease. N Engl J Med 1992; 326: 1693–5

    Article  PubMed  CAS  Google Scholar 

  177. Ostensen M, Hoyeraal HM, Kass E. Tolerance of cyclosporine A in children with refractory juvenile rheumatoid arthritis. J Rheumatol 1988; 15: 1536–8

    PubMed  CAS  Google Scholar 

  178. Pistoia V, Buoncompagni A, Scribanis R, et al. Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis: results of a preliminary study. Clin Exp Rheumatol 1993; 11: 203–8

    PubMed  CAS  Google Scholar 

  179. Reiff A, Rawlings DJ, Shaham B, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 1997; 24: 2436–43

    PubMed  CAS  Google Scholar 

  180. Scholte T, Dannecker G, Thiel HJ, et al. Cyclosporin A in therapy of chronic uveitis in childhood. Ophthalmology 1996; 93: 745–8

    Article  Google Scholar 

  181. Kotaniemi K. Late onset uveitis in juvenile-type chronic polyarthritis controlled with prednisolone, cyclosporin A and methotrexate. Clin Exp Rheumatol 1998; 16: 469–71

    PubMed  CAS  Google Scholar 

  182. Kilmartin DJ, Forrester JV, Dick AD. Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol 1998; 82: 737–42

    Article  PubMed  CAS  Google Scholar 

  183. Ravelli A, De Benedetti F, Viola S, et al. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr 1996; 128: 275–8

    Article  PubMed  CAS  Google Scholar 

  184. Mouy R, Stephan JL, Pillet P, et al. Efficacy of cyclosporin A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr 1996; 129: 750–4

    Article  PubMed  CAS  Google Scholar 

  185. Miller III JJ. Prolonged use of large intravenous steroid pulses in the rheumatic diseases of children. Pediatrics 1980; 65: 989–94

    PubMed  Google Scholar 

  186. Job-Deslandre C, Menkes CJ. Administration of methylprednisolone pulse in chronic arthritis in children. Clin Exp Rheumatol 1991; 9 Suppl. 6: 95–8

    Google Scholar 

  187. Adebajo AO, Hall MA. The use of intravenous pulsed methylprednisolone in the treatment of systemic-onset juvenile chronic arthritis. Br J Rheumatol 1998; 37: 1240–2

    Article  PubMed  CAS  Google Scholar 

  188. Klein-Gitelman MS, Pachman LM. Intravenous corticosteroids adverse reactions are more variable than expected in children. J Rheumatol 1998; 25: 1995–2002

    PubMed  CAS  Google Scholar 

  189. Rimza ME. Complications of corticosteroid therapy. Am J Dis Child 1978; 132: 806–10

    Google Scholar 

  190. Garber EK, Fan PT, Bluestone R. Realistic guidelines of corticosteroid therapy in rheumatic diseases. Semin Arthritis Rheum 1981; 11: 231–56

    Article  CAS  Google Scholar 

  191. Byron MA, Jackson J, Ansell BM. Effect of different corticosteroid regimens on hypothalamic-pituitary-adrenal axis and growth in juvenile chronic arthritis. J R Soc Med 1983; 76: 452–7

    PubMed  CAS  Google Scholar 

  192. Svantesson H. Treatment of growth failure with human growth hormone in patients with juvenile chronic arthritis: a pilot study. Clin Exp Rheumatol 1994; 9 Suppl. 6: 47–50

    Google Scholar 

  193. Davies UM, Rooney M, Preece MA, et al. Treatment of growth retardation in juvenile chronic arthritis with recombinant human growth hormone. J Rheumatol 1994; 21: 153–8

    PubMed  CAS  Google Scholar 

  194. Touati G, Prieur AM, Ruiz JC, et al. Beneficial effects of one-year growth hormone administration to children with juvenile chronic arthritis on chronic steroid therapy: I. Effects on growth velocity and body composition. J Endocrinol Metab 1998; 83: 403–9

    Article  CAS  Google Scholar 

  195. Rooney M, Davies U, Ansell BM, et al. The recombinant growth hormone (rGH) study in juvenile chronic arthritis (JCA) five years on [abstract]. Clin Exp Rheumatol 1995; 13 Suppl. : S63

    Google Scholar 

  196. Davies UM, Jones J, Reeve J, et al. Juvenile rheumatoid arthritis: effect on disease activity and recombinant human growth hormone on insulin-like growth factor-1, insulin-like growth factor binding proteins 1 and 3 and osteocalcin. Arthritis Rheum 1997; 40: 332–40

    Article  PubMed  CAS  Google Scholar 

  197. Reed AM, Haugen M, Pachman LM, et al. Repair of osteoporosis in children with juvenile rheumatoid arthritis. J Pediatr 1993; 122: 693–6

    Article  PubMed  CAS  Google Scholar 

  198. Wardy B, Linsley C, Robinson R. The effects of nutritional supplementation on bone mineral status of children with rheumatic diseases on corticosteroid therapy [abstract]. Arthritis Rheum 1989; 32: S29

    Article  Google Scholar 

  199. Markham A, Bryson HM. Deflazacort: a review of its pharmacological properties and therapeutic efficacy. Drugs 1995; 50: 317–33

    Article  PubMed  CAS  Google Scholar 

  200. Schoemaker LR. Expanding role of biphosphonate therapy in children. J Pediatr 1999; 134: 264–7

    Article  Google Scholar 

  201. Gattinara M, Gallazzi M, Gerloni V, et al. Use of cyclic etidronate in patients with juvenile chronic rheumatic diseases on long-term treatment with steroids [abstract]. Arthritis Rheum 1998; 41: S45

    Google Scholar 

  202. Lepore L, Pennesi M, Barbi E, et al. Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. Clin Exp Rheumatol 1991; 9 Suppl. 6: 33–5

    PubMed  Google Scholar 

  203. Bembi B, Parma A, Bottera H, et al. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 1997; 131: 622–5

    Article  PubMed  CAS  Google Scholar 

  204. Glorieux F, Boshop N, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339: 947–52

    Article  PubMed  CAS  Google Scholar 

  205. Brumsen C, Hamdy NA, Papapoulos SE. Long term effects of biphosphonate on the growing skeleton: studies of young patients with severe osteoporosis. Medicine 1997; 76: 266–83

    Article  PubMed  CAS  Google Scholar 

  206. Liens D, Delmas PD, Meunier PJ. Long term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 1994; 343: 953–4

    Article  PubMed  CAS  Google Scholar 

  207. Van Persijn Van Meerten EL, Kroon HM, Papapoulos SE. Epi- and metaphyseal changes in children caused by administration of biphosphonates. Radiology 1992; 184: 249–54

    Google Scholar 

  208. Lteif AN, Zimmerman D. Biphosphonates for treatment of childhood hypercalcemia. Pediatrics 1998; 102: 990–3

    Article  PubMed  CAS  Google Scholar 

  209. Macarol V, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reaction. Am J Ophthalmol 1994; 118: 220–4

    PubMed  CAS  Google Scholar 

  210. Kellihan MJ, Mangino PD. Pamidronate. Ann Pharmacother 1992;26: 1262–9

    PubMed  CAS  Google Scholar 

  211. Bounameaux HM, Schifferli J, Montani JP, et al. Renal failure associated with intravenous diphosphonates [letter]. Lancet 1983; I: 471

    Article  Google Scholar 

  212. Lufkin AL, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognised problem in gastrointestinal tolerability. Osteoporos Int 1994; 4: 320–2

    Article  PubMed  CAS  Google Scholar 

  213. Dollfus H. Eye involvement in children’s rheumatic diseases. Baillieres Clin Rheumatol 1998; 12: 309–28

    Article  PubMed  CAS  Google Scholar 

  214. Earley A, Cuttica R, McCullough C, et al. Triamcinolone hexacetonide into the knee joint in juvenile chronic arthritis. Clin Exp Rheumatol 1988; 6: 153–5

    PubMed  CAS  Google Scholar 

  215. Eich GF, Halle F, Hodler J, et al. Juvenile chronic arthritis: imaging of the knees and hips before and after steroid injection. Pediatr Radiol 1994; 24: 558–63

    Article  PubMed  CAS  Google Scholar 

  216. Sherry DD, Stein LD, Reed AM, et al. Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids. Arthritis Rheum 1999; 42: 2330–4

    Article  PubMed  CAS  Google Scholar 

  217. Pugh MT, Grosse R, Southwood TR. Multiple joint corticosteroid injections in polyarticular juvenile arthritis: a single-blind one year follow-up study [abstract]. Arthritis Rheum 1995; 38: S283

    Google Scholar 

  218. Job Deslandre C, Menkes CJ. Complications of intraarticular injections of triamcinolone hexacetonide in chronic arthritis in children. Clin Exp Rheumatol 1990; 8: 413–6

    PubMed  CAS  Google Scholar 

  219. Prieur AM. Management in rheumatology. In: Klippel JH, Dieppe PA, editors. Rheumatology. 2nd ed. London: Mosby, 1998: 5–21.1–8

    Google Scholar 

  220. Huppertz HI, Pfuller H. Transient suppression of endogenous cortisol production after intraarticular steroid therapy for chronic arthritis in children. J Rheumatol 1997; 24: 1833–7

    PubMed  CAS  Google Scholar 

  221. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340: 227–8

    Article  PubMed  CAS  Google Scholar 

  222. Silverman ED, Laxer RM, Greenwald M, et al. Intravenous immunoglobulin therapy in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1990; 33: 1015–22

    Article  PubMed  CAS  Google Scholar 

  223. Prieur AM, Adleff A, Debre M, et al. High dose immunoglobulin in the treatment of systemic juvenile chronic arthritis. Clin Exp Rheumatol 1990; 8: 603–9

    PubMed  CAS  Google Scholar 

  224. Silverman ED, Cawkwell GD, Lovell DJ, et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. J Rheumatol 1994; 21: 2353–8

    PubMed  CAS  Google Scholar 

  225. Uziel Y, Laxer RM, Schneider R, et al. WIG therapy in systemic onset juvenile rheumatoid arthritis: a follow up study. J Rheumatol 1996; 23: 910–8

    PubMed  CAS  Google Scholar 

  226. Giannini EH, the Pediatric Rheumatology Study Group. IVIG in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. J Rheumatol 1996; 23: 919–24

    PubMed  CAS  Google Scholar 

  227. Prieur AM. IVIG in Still’s disease: still unproven, still controversial. J Rheumatol 1996; 23: 797–800

    PubMed  CAS  Google Scholar 

  228. Mangge H, Kenzian H, Gallistl S, et al. Serum cytokines in juvenile rheumatoid arthritis: correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum 1995; 88: 211–20

    Article  Google Scholar 

  229. Grom AA, Murray KJ, Luyrink L, et al. Patterns of expression of tumor necrosis factor α, tumor necrosis factor β, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum 1996; 39: 1703–10

    Article  PubMed  CAS  Google Scholar 

  230. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998; 25: 203–6

    PubMed  Google Scholar 

  231. Pernice W, Schuchmann L, Dippel J, et al. Therapy for systemic juvenile rheumatoid arthritis with gamma-interferon: a pilot study of nine patients. Arthritis Rheum 1989; 32: 643–6

    Article  PubMed  CAS  Google Scholar 

  232. Elliott MJ, Maini RN, Feldman M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105–10

    Article  PubMed  CAS  Google Scholar 

  233. Maini RM, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552–63

    Article  PubMed  CAS  Google Scholar 

  234. Elliott MJ, Woo P, Charles P, et al. Suppression of fever and the acute phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumor necrosis factor-alpha (cA2). Br J Rheumatol 1997; 36: 389–93

    Article  Google Scholar 

  235. Garrison L, McDonnel ND. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis 1999; 58 Suppl. I: 165–9

    Google Scholar 

  236. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular rheumatoid arthritis. N Engl J Med 2000; 342: 763–9

    Article  PubMed  CAS  Google Scholar 

  237. Lovell DJ, Giannini EH, Lange M, et al. Safety and efficacy of Enbrel (etanercept) in the extended treatment of polyarticular course JRA [abstract]. Arthritis Rheum 1999; 42: S117

    Article  Google Scholar 

  238. Bresnihan B. Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist. Ann Rheum Dis 1999; 59 Suppl. I: 196–8

    Google Scholar 

  239. St Clair EW. Interleukin 10 treatment for rheumatoid arthritis. Ann Rheum Dis 1999; 59 Suppl. II: I99–102

    Article  Google Scholar 

  240. Maini RM, Taylor PC, Paleolog E, et al. Anti-tumor necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis 1999; 59 Suppl. I: I56–60

    Article  Google Scholar 

  241. Evans CH, Ghivizzani SC, Kang R, et al. Gene therapy for rheumatic diseases. Arthritis Rheum 1999; 42: 1–16

    Article  PubMed  CAS  Google Scholar 

  242. Wicks I, Cooley H, Szer J. Autologous hemopoietic stem cell transplantation: a possible cure for rheumatoid arthritis? Arthritis Rheum 1997; 40: 1005–11

    Article  PubMed  CAS  Google Scholar 

  243. Lowenthal RM, Cohen ML, Atkinson K, et al. Apparent cure of rheumatoid arthritis by bone marrow transplantation. J Rheumatol 1993; 20: 137–40

    PubMed  CAS  Google Scholar 

  244. Slavin S. Treatment of life threatening autoimmune diseases with myeloablative doses of immunosuppressive agents: experimental background and rationale for a BMT. Bone Marrow Transpl 1992; 9: 85–8

    Google Scholar 

  245. Tyndall A, Grathohl A. Bone marrow transplantation in the treatment of autoimmune diseases. Br J Rheumatol 1997; 36: 1–5

    Article  PubMed  CAS  Google Scholar 

  246. Wulffraat N, Van Royen A, Bierings M, et al. Autologous haematopoietic stem-cell transplantation in four refractory juvenile chronic arthritis. Lancet 1999; 353: 550–3

    Article  PubMed  CAS  Google Scholar 

  247. Martini A, Maccario R, Ravelli A, et al. Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis. Arthritis Rheum 1999; 42: 807–11

    Article  PubMed  CAS  Google Scholar 

  248. Quartier P, Prieur AM, Fischer A. Haemopoietic stem-cell transplantation for juvenile chronic arthritis. Lancet 1999; 353: 1885–6

    Article  PubMed  CAS  Google Scholar 

  249. Hagsmaa CJ, Van Piel PL. Combination of second-line anti-rheumatic drugs. Ann Med 1997; 29: 129–73

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Paediatric Immunohaematology and Paediatric Rheumatology, Hôpital Necker-Enfants Malades, Paris, France

    Anne-Marie Prieur & Pierre Quartier

Authors
  1. Anne-Marie Prieur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pierre Quartier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anne-Marie Prieur.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prieur, AM., Quartier, P. Comparative Tolerability of Treatments for Juvenile Idiopathic Arthritis. BioDrugs 14, 159–183 (2000). https://doi.org/10.2165/00063030-200014030-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200014030-00003

Keywords

Search

Navigation